Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus
Use of Single Photon Emission Computed Tomography (SPECT) as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in Subjects Coinfected With HIV and Hepatitis C Virus (HCV)
The purpose of this study is to find if the Single Photon Emission Computed Tomography (SPECT) scan is as effective as a liver biopsy (using a special needle to remove tissue from the liver) in examining liver damage in patients with HIV and hepatitis C virus (HCV).
A standard way to examine the liver for disease has been to perform a liver biopsy. The SPECT scan, which takes a picture of the liver, has been found to be effective in determining liver damage but studies need to be done in patients with hepatitis. This study will compare the effectiveness of the liver biopsy and SPECT scan in determining liver disease in patients with HIV and HCV. The SPECT scan might be a good replacement for the liver biopsy if it is found to be as good as or better than liver biopsies.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Assessment with a liver biopsy is currently the standard of practice to determine the status of liver involvement in patients with HCV. A direct comparison between SPECT results and liver pathology has been examined in patients with liver disease other than infectious hepatitis. SPECT has been found to be more accurate than standard liver-spleen scans in assessing liver pathology. While current data suggest that liver pathology may correlate with SPECT, which specific SPECT parameters are predictive of certain hepatic pathology is unknown. The pilot study will compare SPECT parameters with the results of liver biopsies to determine the limitations of SPECT.
All screened patients are registered into Step 1, in which they receive a radioactive tracer injection and SPECT scan. Specific SPECT parameters will be measured to determine a grading scale corresponding to that used in liver biopsy results. Some patients undergoing a second liver biopsy in A5071 are enrolled into Step 2, with permission from protocol co-chairs, in which a pregnancy test and second SPECT scan are performed. Patients are reimbursed for completing each SPECT scan. SPECT scans or copies are reviewed to establish which parameters correspond to category E of the Knodell stage based on severity of fibrosis.
Tipo di studio
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
California
-
Stanford, California, Stati Uniti, 943055107
- Stanford Univ Med Ctr
-
-
Florida
-
Miami, Florida, Stati Uniti, 331361013
- Univ of Miami School of Medicine
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96816
- Univ of Hawaii
-
-
New York
-
New York, New York, Stati Uniti, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
Rochester, New York, Stati Uniti, 14642
- Univ of Rochester Medical Center
-
Rochester, New York, Stati Uniti, 14642
- Community Health Network Inc
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 275997215
- Univ of North Carolina
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 452670405
- Univ of Cincinnati
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Univ of Pennsylvania
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Univ of Texas, Southwestern Med Ctr of Dallas
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Univ of Washington
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
Patients may be eligible for this study if they:
- Are enrolled in, or will soon enroll in, A5071. Patients may be eligible for the study if they are screening for A5071 and have a liver biopsy and SPECT scan but do not enter A5071. Patients who have stopped taking A5071 study drugs may also be eligible.
- Have had a liver biopsy, or will soon have a liver biopsy.
- Have a SPECT scan either before the liver biopsy or 2 weeks to 8 weeks after a liver biopsy.
- Intend to have the SPECT scan within 7 days of study entry.
Exclusion Criteria
Patients will not be eligible for this study if they:
- Are allergic to chemicals in the radioactive tracer used for the SPECT scan.
- Are pregnant or breast-feeding.
Piano di studio
Come è strutturato lo studio?
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Bruce Shiramizu
- Cattedra di studio: Dickens Theodore
Studiare le date dei record
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ACTG A5096
- AACTG A5096
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .